News
Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback